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Adaptive Deep Brain Stimulation
Controls Levodopa-Induced Side
Effects in Parkinsonian Patients
The potential superior benefits of adaptive deep brain stim-
ulation (aDBS) approaches1 compared to classical, constant-
parameters DBS were already proven by scientific evidence
from different research groups.2-4 aDBS provides better symp-
toms control in Parkinson’s disease patients by adapting the
stimulation parameters to the patient’s clinical state estimated
through the analysis of subthalamic neuronal oscillations (ie,
local field potentials) in the beta band (13-30 Hz).5
Because aDBS administration was never systematically
assessed during prolonged stimulation sessions in more eco-
logic conditions, we tested unilateral aDBS delivered for 2
hours, with specific focus on the concurrent administration
of levodopa treatment, in freely moving parkinsonian
patients.
We therefore randomly administered aDBS and cDBS through
an external wearable prototype6 in 10 PD patients with DBS
electrode implant in 2 different experimental sessions taking
place the 5th and the 6th day after surgery (Fig. 1A). Each
experimental session lasted 2 hours, during which the patient,
after a baseline assessment (OFF DBS and OFF medication,
stimOFF/medOFF), received both levodopa and stimulation
(aDBS or cDBS), thus allowing one to study the interaction
between electrical and pharmacological stimulation (ON DBS
and ON medication, stimON/medON). The patient was blind
to the type of DBS received during the session. The clinical
effects were blindly evaluated through the UPDRS III (motor
part) and the Unified Dyskinesia Rating Scale (UDysRS).
According to the gold standard, the clinical assessment was per-
formed by a blinded video rater (rigidity scores were excluded
from the analysis). The total electrical energy delivered (TEED)
was used for energy efficiency assessment and adverse events
were collected for safety assessment.
The clinical scores were not significantly different
between the 2 experimental sessions at baseline (stimOFF/
medOFF UPDRS III, aDBS vs cDBS: 37.0 6 16.8 vs 36.6
6 16.2; F1,9 5 0.2, P > .05). When the patient was under
the effect of both levodopa and DBS (stimON/medON),
we observed a similar improvement on global motor
symptoms regardless to the type of DBS (UPDRS III per-
cent change from baseline, aDBS vs cDBS: 246.1% 6
10.5% vs 240.1% 6 17.5%; F1,9 5 0.6, P > .05; Fig.
1B). Conversely, in this condition, aDBS was more effec-
tive on dyskinesias than cDBS (UDysRS score, aDBS vs
cDBS: 11.7 6 67 vs 15.0 6 8.7; F1,9 5 6.1, P 5 .02; Fig.
1C). These results were obtained with an average power
saving of 73.6% 6 22.9% in aDBS compared with cDBS
(mean TEED aDBS vs cDBS: 44.6 6 47.9 lW vs 158.7 6
69.7 lW; F1,8 5 30.4, P 5 .0005). Throughout the entire
experiment, we did not observe any serious adverse event
specifically linked to DBS.
These results support the idea that aDBS, being effec-
tive, efficient, and safe, when administered concomitantly
to levodopa could help clinicians limit the severity of side
effects induced by the transient summation of DBS stimu-
lation and pharmacological therapy. However, the acute
experimental setting, characterized by a microlesional
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effect and by the presence of edema, is a major limitation
for the generalizability of our results that need to be con-
firmed by other studies conducted in a more chronic con-
dition, possibly with implantable devices.
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FIG. 1. (A) Experimental design of each experimental session. Clinical effects were evaluated using the motor part of the Unified PD Rating Scale
(UPDRS III) and the Unified Dyskinesia Rating Scale (UDysRS III and IV) during the concurrent administration of DBS (adaptive deep brain stimula-
tion [aDBS] or conventional DBS [cDBS]) and levodopa. (B) The UPDRS III and UDysRS scores during aDBS and cDBS, normalized for the maxi-
mum score between aDBS and cDBS. (C) Total electrical energy delivered (TEED) per unit of time (lW) for aDBS (white color) and cDBS (gray
color). Error bars represent the standard error (SE). med, medication; stim, stimulation.
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